Lead your advanced heart failure (AHF) patients on a different course of action with HeartMate II

When medical options are no longer enough to provide meaningful benefits, take heart in knowing there is more you can do.

Understanding the life-changing potential of left ventricular assist devices (LVADs), the experience and benefits of HeartMate II—the LVAD market leader—and how to identify appropriate patients for timely referral reflects your commitment to your AHF patients’ long-term outcomes.


Learn about the HeartMate II System


Download our complete brochure


Listen to an expert panel discuss LVADs

LVADs offer AHF patients another chance to survive... and thrive

American Heart Association (AHA) guidelines identify appropriate therapeutic alternatives for each stage of heart disease5

New York Heart Association (NYHA) Classification5

After heart transplantation, a left ventricular assist device, or LVAD, is the only option that can significantly and meaningfully improve the symptoms of advanced heart failure (AHF).1 That’s good news for the over 5 million Americans who have heart failure.2 And with the scarcity of donor organs limiting the supply available for heart transplants,3 LVAD implantation has outpaced heart transplants.4


That’s why leading organizations such as the NYHA and AHA have identified classifications and guidelines for treating this epidemic—including when it’s time to seek the life-changing benefits of an LVAD.5

References:
1. Miller LW. Left ventricular assist devices are underutilized. Circulation. 2011;123(14):1552-1558. 2. ACC/AHA update guideline for management of heart failure. American Heart Association website. http://newsroom.heart.org/news/acc-aha-update-guideline-for-management-of-heart-failure. Accessed June 11, 2014. 3. Fang JC. Rise of the machines—left ventricular assist devices as permanent therapy for advanced heart failure. N Engl J Med. 2009;361(23):2282-2285. 4. Data on file. September 2014. Pleasanton, CA. Thoratec Corp. 5. Jessup M, Brozena S. Heart failure. N Engl J Med. 2003;348(20):2007-2018.


Meet Aleta—and her dog—and see how HeartMate II got them walking together again


Watch our Innovations in Advanced Heart Failure video

Offer HOPE to your advanced heart failure patients
If patients have 1 or more risk factors...
...it's time for a HeartMate II® consultation
Learn more

Patients may be considered for a left ventricular assist device (LVAD) for different therapeutic goals:

Destination Therapy (DT) patients: A growing population

DT patients are ineligible for heart transplants most often due to1,2:

Patients eligible for DT fall into a particular window of health, compromised enough to require an LVAD, but otherwise healthy enough to survive and thrive through the procedure.1

References:
1. Flint KM, Matlock DD, Lindenfeld J, Allen LA. Frailty and the selection of patients for destination therapy left ventricular assist device. Circ Heart Fail. 2012;5(2):286-293. 2. HeartMate II Left Ventricular Assist System: Instructions for Use. 105747.B. Pleasanton, CA: Thoratec Corp.; 2013. 3. Russell SD, Miller LW, Pagani FD. Advanced heart failure: a call to action. Congest Heart Fail. 2008;14(6):316-321.


Find out how HeartMate II put Sagar back in his garden


Learn more about the clinical criteria


Learn more about LVAD and transplant approaches


Use our diagnostic checklist to help evaluate patients

HeartMate II: The amazing function of an LVAD, made simple for your patient

+
+
+

The life-changing benefits of HeartMate II, the world’s leading left ventricular assist device (LVAD)

Heart pump
HeartMate II is implanted just below the diaphragm in the abdomen and connects the left ventricle to the aorta. Rather than replacing the heart, HeartMate II assists the heart in circulating oxygen-rich blood throughout the body.8
Battery/Power
Rechargeable batteries weigh only 1 pound and provide 10 to 12 hours of uninterrupted support. A power module allows HeartMate II to be plugged into any electrical outlet when the patient is stationary.
Pocket Controller
The 1-pound, easy-to-use Pocket Controller alerts patients of any action they need to take regarding their HeartMate II. The Pocket Controller connects to the heart pump via the thin driveline, which sends power and operating signals to the pump.

Based on published data from multicenter experience and separate studies, which may involve different patient populations and other variables. Please refer to the HeartMate II Instructions for Use about indications, contraindications, adverse events, warnings, and precautions (http://www.thoratec.com/medical-professionals/resource-library/ifus-manuals/heartmate-ll-lvad.aspx).

References:
1. Park SJ, Milano CA, Tatooles AJ, et al; for the HeartMate II Clinical Investigators. Outcomes in advanced heart failure patients with left ventricular assist devices for destination therapy. Circ Heart Fail. 2012;5(2):241-248. 2. Rose EA, Gelijns AC, Moskowitz AJ, et al; for the Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure (REMATCH) Study Group. Long-term use of a left ventricular assist device for end-stage heart failure. N Engl J Med. 2001;345(20):1435-1443. 3. Boyle AJ, Russell SD, Teuteberg JJ, et al. Low thromboembolism and pump thrombosis with the HeartMate II left ventricular assist device: analysis of outpatient anti-coagulation. J Heart Lung Transplant. 2009;28(9):881-887. 4. Starling RC, Naka Y, Boyle AJ, et al. Results of the post-U.S. Food and Drug Administration-approval study with a continuous flow left ventricular assist device as a bridge to heart transplantation: a prospective study using INTERMACS (Interagency Registry for Mechanically Assisted Circulatory Support). J Amer Coll Cardiol. 2011;57(19):1890-1898. 5. Data on file. September 2014. Pleasanton, CA. Thoratec Corp. 6. HeartMate II Left Ventricular Assist System: Instructions for Use. 105747.B. Pleasanton, CA: Thoratec Corp.; 2013. 7. John R, Naka Y, Smedira NG, et al. Continuous flow left ventricular assist device outcomes in commercial use compared with the prior clinical trial. Ann Thorac Surg. 2011;92(4):1406-1413. 8. HeartMate II Left Ventricular Assist System: Patient Handbook.106022.E. Pleasanton, CA: Thoratec Corp.; 2013.


Learn how John went from breathless to being on the golf course


Watch how HeartMate II works

Take confidence in referring patients for an LVAD with HeartMate II

HeartMate II Survival Rates vs
Optimal Medical Management (OMM)
4-6,*

The most widely used and extensively studied left ventricular assist device (LVAD) in the world1,2

Years of clinical experience show a high survival rate in both Destination Therapy (DT) and Bridge to Transplantation (BTT) patients4,5

---

% of Patients Classified as NYHA Class I and Class II
Post HeartMate II Implant
4,*

Dramatic, sustained functional improvement, with the majority of patients returning to NYHA Class I or Class II over time4

HeartMate II allows patients to get moving again7

The 6-minute walk test (6MWT) is an objective tool designed to measure activity intolerance in patients with heart failure8

Based on published data from multicenter experience and separate studies, which may involve different patient populations and other variables.

---

HeartMate II Stroke Rates in Postapproval Studies

HeartMate II has the lowest published stroke rate of any continuous flow LVAD6,9,10,*

Based on published data from multicenter experience and separate studies, which may involve different patient populations and other variables. Please refer to the HeartMate II Instructions for Use about indications, contraindications, adverse events, warnings, and precautions (http://www.thoratec.com/medical-professionals/resource-library/ifus-manuals/heartmate-ll-lvad.aspx).

References:
1. Lund H, Gabrielsen A, Tirén L, Hallberg A, El Karlsson K, Eriksson MJ. Derived and displayed power consumption, flow, and pulsatility over a range of HeartMate II left ventricular assist device settings. ASAIO J. 2012;58(3):183-190. 2. Rodriguez LE, Suarez EE, Loebe M, Bruckner BA. Ventricular assist devices (VAD) therapy: new technology, new hope? Methodist DeBakey Cardiovasc J. 2013;9(1):32-37. 3. Data on file. September 2014. Pleasanton, CA. Thoratec Corp. 4. Park SJ, Milano CA, Tatooles AJ, et al; for the HeartMate II Clinical Investigators. Outcomes in advanced heart failure patients with left ventricular assist devices for destination therapy. Circ Heart Fail. 2012;5(2):241-248. 5. Rose EA, Gelijns AC, Moskowitz AJ, et al; for the Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure (REMATCH) Study Group. Long-term use of a left ventricular assist device for end-stage heart failure. N Engl J Med. 2001;345(20):1435-1443. 6. Starling RC, Naka Y, Boyle AJ, et al. Results of the post-U.S. Food and Drug Administration-approval study with a continuous flow left ventricular assist device as a bridge to heart transplantation: a prospective study using INTERMACS (Interagency Registry for Mechanically Assisted Circulatory Support). J Amer Coll Cardiol. 2011;57(19):1890-1898. 7. John R, Naka Y, Smedira NG, et al. Continuous flow left ventricular assist device outcomes in commercial use compared with the prior clinical trial. Ann Thorac Surg. 2011;92(4):1406-1413. 8. Guazzi M, Dickstein K, Vicenzi M, Arena R. Six-minute walk test and cardiopulmonary exercise testing in patients with chronic heart failure. Circ Heart Fail. 2009;2(6):549-555. 9. Boyle AJ, Russell SD, Teuteberg JJ, et al. Low thromboembolism and pump thrombosis with the HeartMate II left ventricular assist device: analysis of outpatient anti-coagulation. J Heart Lung Transplant. 2009;28(9):881-887. 10. Aaronson KD, Slaughter MS, Miller LW, et al. Use of an intrapericardial, continuous-flow, centrifugal pump in patients awaiting heart transplantation. Circulation. 2012;125(25):3191-3200. 11. Jorde UP, Kushwaha SS, Tatooles AJ, et al. Results of the destination therapy post-Food and Drug Administration approval study with a continuous flow left ventricular assist device: a prospective study using the INTERMACS registry (Interagency Registry for Mechanically Assisted Circulatory Support). J Am Coll Cardiol. 2014;63(17):1751-1757.


See how LVAD clinical data have improved over time


Learn more about stroke rates in LVADs

Offer patients new hope for increased survival and improved quality of life with HeartMate II

1. Art Pierskalla
2. Laura Huber
3. Marvin Smeal
4. Reiss Tatum
5. Kristi Mardis
and Tony McNatt

Destination Therapy (DT) patient case study: Art Pierskalla, 71

History:
Idiopathic dilated cardiomyopathy
  • Deemed ineligible for heart transplant due to age
  • Managing symptoms with digoxin, diuretic, amiodarone, and warfarin
Presentation:
NYHA Class IV heart failure
  • Inability to walk 2 blocks without shortness of breath
  • CRT nonresponder
  • BUN > 40 mg/dL
  • Serum creatinine > 1.8 mg/dL
Desired outcome:
Improved quality of life
Cardiologist recommendation:
Referred to Advanced Heart Failure Center for LVAD evaluation
Resulting action:
Patient elected mechanical circulatory support (MCS) intervention, choosing implantation with HeartMate II LVAD as Destination Therapy. Currently surpassed 8 years on support
Baseline 24 Months
Post Implant
NYHA Class IV I
Cardiac output (LPM) 2.4 7.1
Serum creatinine (mg/dL) 2.3 1.8
BUN (mg/dL) 43 21
Total bilirubin (mg/dL) 0.6 0.5
Minnesota Living With Heart Failure score 72 21
Kansas City Cardiomyopathy score 49 87


Hear more from
patients about
what HeartMate II
did for them

Continue your patient relationship through Thoratec® Shared Care

Shared Care is a partnership program to comanage HeartMate II patients and enable a smooth transition home.

Shared Care allows recipients to resume their regular life and maintain a relationship with their community cardiologist.

The Thoratec Shared Care program provides you with:


Download our
Shared Care brochure


Hear a colleague’s perception of
Shared Care

Call your Thoratec® Representative today

Now that you know more about the life-changing benefits of HeartMate II, take the next step toward a new world for your advanced heart failure patients.

Contact us to request a visit from a Thoratec Representative, or use our search tool to find one of over 170 HeartMate II Centers across the country.

Find a Center

IMPORTANT NOTICE
The listing of HeartMate II Centers is compiled by Thoratec as a reference tool for physicians and patients seeking to locate a VAD center. All the centers listed have experience with Thoratec products and have received training. None have paid or received a fee to be listed in this database.

This database may not include all centers that use or have used Thoratec products. Similarly, this database does not include all centers who do LVAD implantation.

Thoratec does not verify or monitor the performance, licensure, certification, quality, or qualifications of any center listed in the database and is not responsible for the medical advice, care, or treatment provided by the centers included in this database.

The decision whether, and when, to contact a center belongs to patients and their physicians. When choosing a center, we encourage you to weigh factors such as the experience of the center and any other criteria you deem relevant.

For information on the indications, contraindications, adverse events, warnings, and precautions of HeartMate II, click here.

By accessing and using the Find a HeartMate II Center database, you acknowledge that you understand and agree with the information set forth above.

OPEN
CLOSE

Contact Us

Use the form below to request more information.

*Required Information



Please keep me up-to-date via email on Thoratec® and the latest advancements in
heart failure treatment.






You are now leaving HeartMateII.com. Thoratec does not review the information on this website and/or database for content, accuracy, or completeness. Use of and access to this information is subject to the terms, limitations, and conditions set by the website and/or database producer. Thoratec makes no representation as to the accuracy or any other aspect of the information contained on such website and/or database, nor does Thoratec necessarily endorse such website and/or database. Continue